Article Text

Download PDFPDF
Colchicine in coronary artery disease
  1. Arnav Katira1,
  2. Ravish Katira2
  1. 1 Department of Medicine, Salford Royal NHS Foundation Trust, Salford, UK
  2. 2 Cardiology Department, St Helens and Knowsley Teaching Hospitals NHS Trust, Prescot, UK
  1. Correspondence to Dr Arnav Katira, Salford Royal NHS Foundation Trust, Salford M6 8HD, UK; arnavkatira{at}


Coronary artery disease (CAD) is a major cause of morbidity and mortality worldwide. Inflammation has been seen to be a key feature of atherosclerosis and CAD, with a raised C-reactive protein being a marker of poor prognosis. Thus, the role of anti-inflammatory agents has been investigated in CAD. Colchicine is a well-known, inexpensive drug with marked anti-inflammatory effects. Here, we discuss the role of colchicine in stable CAD and post-acute coronary syndrome. We suggest that colchicine may play a key role in prevention of cardiovascular events in patients with stable and unstable CAD as colchicine is associated with a reduction in the rate of myocardial infarction and other major cardiovascular outcomes.

  • cardiology
  • clinical pharmacology
  • myocardial infarction
  • coronary heart disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors Both AK and RK were involved in the writing of this article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.